Neurocrine biosciences announces publication of primary cahtalyst™ adult phase 3 study results of crinecerfont for the treatment of cah in the new england journal of medicine
- cahtalyst™ adult phase 3 study met primary and important key secondary endpoints, with crinecerfont treatment decreasing androstenedione levels and enabling glucocorticoid dose reduction while maintaining androstenedione control - 62.7% of crinecerfont participants achieved a physiologic glucocorticoid dose while maintaining androstenedione control versus 17.5% of placebo participants - favorable trends in endpoints reflecting consequences of supraphysiologic glucocorticoid dosing - crinecerfont was generally well tolerated san diego , june 3, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that the primary study results from its cahtalyst™ phase 3 study investigating crinecerfont for the treatment of adults ages 18 and older with congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency have been published in the new england journal of medicine online edition and will appear in a future print issue of the journal. the study met the primary and important key secondary endpoints related to androgen reduction (during an initial glucocorticoid-stable period) and glucocorticoid (gc) dose reduction while maintaining androgen control.
NBIX Ratings Summary
NBIX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission